- Home
- ICG vs PHAT Comparison
ICG vs PHAT Comparison
Compare ICG & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICG
- PHAT
- Stock Information
- Founded
- ICG 2017
- PHAT 2018
- Country
- ICG China
- PHAT United States
- Employees
- ICG N/A
- PHAT N/A
- Industry
- ICG Semiconductors
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- ICG Technology
- PHAT Health Care
- Exchange
- ICG Nasdaq
- PHAT Nasdaq
- Market Cap
- ICG 559.6M
- PHAT 465.0M
- IPO Year
- ICG 2023
- PHAT 2019
- Fundamental
- Price
- ICG $4.33
- PHAT $6.96
- Analyst Decision
- ICG Strong Buy
- PHAT Strong Buy
- Analyst Count
- ICG 1
- PHAT 4
- Target Price
- ICG $11.00
- PHAT $23.00
- AVG Volume (30 Days)
- ICG 587.3K
- PHAT 971.9K
- Earning Date
- ICG 02-26-2025
- PHAT 03-06-2025
- Dividend Yield
- ICG N/A
- PHAT N/A
- EPS Growth
- ICG N/A
- PHAT N/A
- EPS
- ICG 0.11
- PHAT N/A
- Revenue
- ICG $34,648,799.00
- PHAT $26,270,000.00
- Revenue This Year
- ICG N/A
- PHAT $7,622.43
- Revenue Next Year
- ICG $74.94
- PHAT $236.87
- P/E Ratio
- ICG $38.92
- PHAT N/A
- Revenue Growth
- ICG 202.16
- PHAT N/A
- 52 Week Low
- ICG $2.80
- PHAT $6.07
- 52 Week High
- ICG $12.04
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- ICG 47.12
- PHAT 37.02
- Support Level
- ICG $3.81
- PHAT $6.36
- Resistance Level
- ICG $4.66
- PHAT $7.20
- Average True Range (ATR)
- ICG 1.64
- PHAT 0.48
- MACD
- ICG -0.11
- PHAT 0.08
- Stochastic Oscillator
- ICG 16.56
- PHAT 30.48
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.